Alternative Splicing, RNA Editing, and the Current Limits of Next Generation Sequencing

The advent of next generation sequencing (NGS) has fostered a shift in basic analytic strategies of a gene expression analysis in diverse pathologies for the purposes of research, pharmacology, and personalized medicine. What was once highly focused research on individual signaling pathways or pathway members has, from the time of gene expression arrays, become a global analysis of gene expression that has aided in identifying novel pathway interactions, the discovery of new therapeutic targets, and the establishment of disease-associated profiles for assessing progression, stratification, or a therapeutic response. But there are significant caveats to this analysis that do not allow for the construction of the full picture. The lack of timely updates to publicly available databases and the hit and miss deposition of scientific data to these databases relegate a large amount of potentially important data to garbage, begging the question, how much are we really missing? This brief perspective aims to highlight some of the limitations that RNA binding/modifying proteins and RNA processing impose on our current usage of NGS technologies as relating to cancer and how not fully appreciating the limitations of current NGS technology may negatively affect therapeutic strategies in the long run.

Automated summary

The emergence of next generation sequencing (NGS) has revolutionized gene expression analysis, allowing for global analysis and identification of novel pathway interactions. However, limitations in publicly available databases and inconsistent deposition of scientific data hinder the construction of a comprehensive picture. This perspective highlights the impact of RNA binding/modifying proteins and RNA processing on NGS technologies in cancer research and emphasizes the importance of fully understanding these limitations.